CMOs are exploring the potential of mammalian cell culture production amidst soaring demand for biopharmaceutical contract manufacturing services. Incumbents, such as Charles River and Lonza have furthered investments in mammalian cells. To illustrate, in May 2021, Lonza announced pouring USD 936 million to bolster the footprint of mammalian drug substance manufacturing sites in the U.S. and...
English
Arabic
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian